Full Logo - OKYO .jpg
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
October 09, 2023 07:00 ET | OKYO Pharma LTD
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with...
Full Logo - OKYO .jpg
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center         
July 28, 2023 07:01 ET | OKYO Pharma LTD
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCPSecond clinical...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members
February 17, 2022 17:42 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
TuftsCSDD-Logo-Color.jpg
Protocol Design Optimization Is Starting to Improve Clinical Study Performance, According to the Tufts Center for the Study of Drug Development
September 09, 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 9, 2014) - Efforts by drug companies to streamline and improve the execution of clinical study designs -- to counter mounting costs and shorten development times...
TuftsCSDD-Logo-Color.jpg
Drug Company Collaborations to Reduce Development Risk Are Increasing, According to Tufts Center for the Study of Drug Development
August 07, 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 7, 2014) - As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are...
TuftsCSDD-Logo-Color.jpg
Orphan Drug Approvals Have Increased, But High Costs Pose Challenges for Patients, According to the Tufts Center for the Study of Drug Development
July 10, 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 10, 2014) - Although the pace of approvals for new orphan drugs -- medicines that treat relatively rare conditions -- have increased in the United States and Europe...
TuftsCSDD-Logo-Color.jpg
Risk-Sharing Drug Development Programs Experience Longer Development Times, According to the Tufts Center for the Study of Drug Development
May 08, 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 8, 2014) - Drug development programs that involve several partners who share clinical development risks accounted for about half of all new therapeutic drug approvals...
TuftsCSDD-Logo-Color.jpg
Drug Developers Circumspect About Using Social Media in Clinical Research, According to the Tufts Center for the Study of Drug Development
March 06, 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 6, 2014) - Social media is gaining ground as an important tool to improve the clinical research process through more effective engagement of patient communities, but...
TuftsCSDD-Logo-Color.jpg
New Breakthrough Therapy Designation Has Potential to Shorten Development Time Considerably, According to the Tufts Center for the Study of Drug Development
January 23, 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 23, 2014) - The recently launched Breakthrough Therapy Designation (BTD) program in the United States, aimed at expediting development and review of drugs intended to...
TuftsCSDD-Logo-Color.jpg
Drug Developers Are Implementing New Strategies for Use of Comparator Drugs in Clinical Trials, According to Tufts Center for the Study of Drug Development
January 16, 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 16, 2014) - Drug developers are aggressively implementing new strategies to improve their access to and use of comparator drugs, which are used in clinical trials to...